Acetylon Pharmaceuticals: Acetylon Presents Preclinical Data Demonstrating The Utility Of Selective HDAC1,2 Inhibition By ACY-957 To Induce Gamma Globin (HBG) Protein Expression For The Treatment Of Sickle Cell Disease And Beta-Thalassemia

Acetylon Pharmaceuticals: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst� and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Acetylon Pharmaceuticals: Celgene buys part of Boston cancer drug firm

Acetylon Pharmaceuticals: Celgene Acquires Acetylon, Will Spin Out Startup

Acetylon Pharmaceuticals: Acetylon Announces Upcoming Scientific Presentations On The Use Of Selective HDAC Inhibitors In Treating Genetic Blood Disorders And Cancers

Acetylon Pharmaceuticals: BRIEF-Acetylon Pharmaceuticals entered into an agreement to be acquired by Celgene Corporation

Press Release: Acetylon Pharmaceuticals : Cognitive Impairment Therapeutic Pipeline Review H2 2016 Major Key Players Analysis